People · Operator
Named in public records as an officer, director or promoter · active 2011–2019 · Pharmaceuticals, Healthtech, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Melinta Therapeutics, Inc. /New/ | — | Pharmaceuticals | Series D+ | $346.8M | $4.9B | 2012 |
| CSA Medical, Inc. | — | Healthtech | Series C | $156.7M | $484.1M | 2011 |
| Vascular Pharmaceuticals, Inc. | — | Biotechnology | Series B | $47.3M | $119.1M | 2012 |
| Innocrin Pharmaceuticals Holdings, LLC | — | Pharmaceuticals | Series B | $42.1M | $204.0M | 2015 |
| Aldagen Inc | — | Biotechnology | Series A | $9.5M | $21.1M | 2011 |
Richard Kent at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard Kent on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Johnson | 1 | 25 |
| Garheng Kong | 1 | 16 |
| B. Jefferson Clark | 1 | 12 |
| PAUL LAVIOLETTE | 1 | 12 |
| Tara Butler | 1 | 12 |
| David Gill | 1 | 8 |
| Matthew Christensen | 1 | 8 |
| S Edward Torres | 1 | 8 |
| William Moore | 1 | 7 |
| Dov Goldstein | 1 | 6 |
| FRED ESHELMAN | 1 | 5 |
| Richard Shea | 1 | 5 |
| James Rosen | 1 | 4 |
| William W Brooke | 1 | 4 |
| John H Johnson | 1 | 4 |
| Douglas Reed | 1 | 4 |
| Steven Weinstein | 1 | 4 |
| P. Sherill Neff | 1 | 3 |
| Vaughn Kailian | 1 | 3 |
| I Wistar Morris | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.